Clinical trial
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive…
NCT00431704 · National Cancer Institute, Naples, Other · Unknown status
Key facts
| NCT number | NCT00431704 |
|---|---|
| Title | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer |
| Official title | Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study |
| Acronym | VinCaT |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | vinorelbine, carboplatin, trastuzumab |
| Enrollment | 39 |
| Start date | Oct 1, 2007 |
| Primary completion | Dec 1, 2023 |
| Completion | Dec 1, 2023 |
| First posted | Feb 6, 2007 |
| Last update posted | Mar 24, 2023 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: